Table 1 :

Clinical characteristics of the 32 patients included in the study, with comparison between epidermal necrolysis and lichenoid/unclassified dermatoses

	All patients N=32	Epidermal necrolysis spectrum N=11	Lichenoid/unclassified dermatoses N=21	p-value
Female sex, n (%)	15 (47)	5 (45)	10 (48)	1
Median age (range), years	60 (21–85)	63 (57–72)	59 (21–85)	0.53
Type of cancer	Lung n=13 Melanoma n=11 Liver n=4 Kidney n=1 Thyroid n=1 Thymus n=1 Unknown n=1	Lung n=5 Melanoma n=2 Liver n=1 Kidney n=1 Thymus n=1 Unknown n=1	Lung n=8 Melanoma n=9 Liver n=3 Thyroid n=1	0.72 0.25
Median time to onset (range), days	52 (3–420)	34 (5–90)	53 (3–420)	0.06
Fever, n (%)	19 (59)	9 (82)	10 (48)	0.13
Maculopapular exanthema, n (%)	25 (78)	9 (82)	16 (76)	1
Lichenoid lesions, n (%)	14 (44)	4 (36)	10 (48)	0.71
Purpuric macules, n (%)	21 (66)	10 (91)	11 (52)	0.05
Blisters, n (%)	27 (84)	11 (100)	16 (76)	0.14
Nikolsky and or detachment > 5 cm, n (%)	21 (66)	9 (82)	12 (57)	0.25
Initial detached-detachable BSA, % (range)	5 (0–45)	10 (0–35)	2 (0–45)	0.25
Maximal detached-detachable BSA, % (range)	18 (1–100)	35 (2–100)	8 (1–74)	0.01
Mucous membrane involvement, n (%)
Oral	29 (91)	10 (91)	19 (90)	1
Laryngeal	8 (25)	3 (27)	5 (24)	1
Genital-anal	9 (28)	2 (18)	7 (33)	0.44
Ocular	15 (47)	8 (73)	7 (33)	0.06
Median baseline SCORTEN (ext)	3 (1–5)	3 (2–5)	3 (1–5)	0.29
Median lenght of hospitalization (range), days	14 (0–121)	17 (3–121)	14 (0–45)	0.59
Treatment, n
Supportive care only	3 (9)	2 (18)	1 (5)	0.54
Topical steroids	16 (50)	1 (9)	15 (71)	0.002
Systemic steroids	26 (81)	8 (73)	18 (86)	0.39
And/or others (IgIV, G-CSF, ciclo, MMF, phototherapy palms/soles	10 (31)	5 (45)	5 (24)	0.25
Median duration of steroids (range), days	30 (3–120)	30 (25–60)	25 (3–120)	0.29
Healed at 6 weeks, n (% among alive patients)	18 (56)	5 (71)	13 (62)	0.46
Death at 6 weeks, n (%)	8 (25)	4 (36)	4 (19)	0.40
Death at last news, n (%)	20 (62)	9 (82)	11 (52)	0.14